Catalog No.
PVV00901
Species reactivity
SARS-CoV-2
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant SARS-CoV-2 S-RBD & E Protein & M Protein (S-RBD(Arg319-Phe541) & E(Arg38-Val75) & M(Arg101-Gln222)).
Tested applications
ELISA: 1:4000-1:8000, WB: 1:1000-1:4000
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, RBD, Envelope small membrane protein, E, sM protein, E, Membrane protein, M, E1 glycoprotein, Matrix glycoprotein, Membrane glycoprotein, M, SARS-CoV-2
Purification
Purified by antigen affinity column.
Accession
P0DTC2 & P0DTC4 & P0DTC5
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D., PMID:40512442
Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH)., PMID:40498774
Identifying Neurological Autoantibodies in COVID-19: mGluR2 as a Marker of Immune Dysregulation During the Omicron Outbreak in China., PMID:40343769
Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with lung infection and tissue-damage biomarkers., PMID:40339608
Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds., PMID:40076865
Carbon monoxide inhibits human bronchial epithelial CCL5 and IL-6 secretion induced by SARS-CoV-2 spike RBD protein., PMID:40058446
Selective Control by Pistacia vera L. and Its Carotenoid Zeaxanthin on SARS-CoV-2 Virus., PMID:40004129
Artificial-Intelligence Bio-Inspired Peptide for Salivary Detection of SARS-CoV-2 in Electrochemical Biosensor Integrated with Machine Learning Algorithms., PMID:39996977
Decoding SARS-CoV-2 variants: Mutations, viral stability, and breakthroughs in vaccines and therapies., PMID:39987705
Self-assembled proteomimetic (SAP) with antibody-like binding from short PNA-peptide conjugates., PMID:39951509
Impact of immunosuppressive regimens on antibody response after COVID-19 vaccination among Thai kidney transplant recipients., PMID:39931482
Real-life observation of wildfire smoke-impaired COVID-19 vaccine immunity., PMID:39924122
The Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity., PMID:39865044
COVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers., PMID:39861867
Establishment of a Yeast Two-Hybrid-Based High-Throughput Screening Model for Selection of SARS-CoV-2 Spike-ACE2 Interaction Inhibitors., PMID:39859397
Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines., PMID:39772069
Association of the immunogenicity of intramuscular SARS-CoV-2 mRNA vaccination with computed tomography muscle images in patients with muscular disorders., PMID:39759503
Development of a Nanobody-Alkaline Phosphatase Fusion Protein for Detection of SARS-CoV-2 Spike Protein in a Fluorescence Enzyme Immunoassay., PMID:39699064
AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors., PMID:39535926
Anti-severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain antibody levels in patients with systemic lupus erythematosus based on vaccination status and related factors in Indonesia., PMID:39525676
Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial., PMID:39482336
S-RBD-modified and miR-486-5p-engineered exosomes derived from mesenchymal stem cells suppress ferroptosis and alleviate radiation-induced lung injury and long-term pulmonary fibrosis., PMID:39462403
Oxoammonium salts exert antiviral effects against coronavirus via denaturation of their spike proteins., PMID:39397158
Evaluation of an Affinity-Enhanced Anti-SARS-CoV2 Nanobody Design Workflow Using Machine Learning and Molecular Dynamics., PMID:39356775
The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria-Tetanus-Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity., PMID:39340062
Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study., PMID:39339957
Comparative Analysis of QCM and Electrochemical Aptasensors for SARS-CoV-2 Detection., PMID:39329806
A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants., PMID:39303003
The Protection Level of S-RBD SARS-CoV-2 Immunoglobulin G Antibodies Using the Chemiluminescent Immunoassay Compared to the Surrogate Virus Neutralization Test Method., PMID:39202264
Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge., PMID:39189731
XBB.1.16-RBD-based trimeric protein vaccine can effectively inhibit XBB.1.16-included XBB subvariant infection., PMID:39156763
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial., PMID:39137572
Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study., PMID:39137369
Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia., PMID:39129572
Biosensor-based active ingredient recognition system for screening potential small molecular Severe acute respiratory syndrome coronavirus 2 entry blockers targeting the spike protein from Rugosa rose., PMID:39126351
Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan., PMID:39088986
Impact of Missense Mutations on Spike Protein Stability and Binding Affinity in the Omicron Variant., PMID:39066312
Stability of Neutralizing Antibody of PastoCoAd Vaccine Candidates against a Variant of Concern of SARS-CoV-2 in Animal Models., PMID:39044638
Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant., PMID:39002905
Vaccination against COVID-19 among healthcare workers as a cocoon strategy for people living with HIV., PMID:38983868
A Unique mRNA Vaccine Elicits Protective Efficacy against the SARS-CoV-2 Omicron Variant and SARS-CoV., PMID:38932334
Role of N343 glycosylation on the SARS-CoV-2 S RBD structure and co-receptor binding across variants of concern., PMID:38864493
Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting., PMID:38845303
Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study., PMID:38793698
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination., PMID:38706402
Dynamics of SARS-CoV-2 antibodies after natural infection: insights from a study on Pasteur Institute of Tunis employees., PMID:38693671
SARS-CoV-2 cellular and humoral responses in vaccine-naive individuals during the first two waves of COVID-19 infections in the southern region of The Netherlands: a cross-sectional population-based study., PMID:38686954
Boosting the immunogenicity of the CoronaVac SARS-CoV-2 inactivated vaccine with Huoxiang Suling Shuanghua Decoction: a randomized, double-blind, placebo-controlled study., PMID:38633263
Evaluation of SARS-CoV-2 Humoral Response Following Vaccination with ChAdOx1 nCoV-19 (Covishield™) and/or Sinopharm, BBIBP-CorV (Vero cell™)., PMID:38615227
Targeted Drug Delivery to ACE2+ Cells Using Engineered Extracellular Vesicles: A Potential Therapeutic Approach for COVID-19., PMID:38551053
For research use only. Not for human or drug use.
